Publication: Treatment of nephrotic syndrome with levamisole
Submitted Date
Received Date
Accepted Date
Issued Date
1980-01-01
Copyright Date
Announcement No.
Application No.
Patent No.
Valid Date
Resource Type
Edition
Resource Version
Language
File Type
No. of Pages/File Size
ISBN
ISSN
00223476
eISSN
Scopus ID
WOS ID
Pubmed ID
arXiv ID
Call No.
Other identifier(s)
2-s2.0-0018830936
Journal Title
Volume
Issue
item.page.oaire.edition
Start Page
End Page
Access Rights
Access Status
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Physical Location
Bibliographic Citation
The Journal of Pediatrics. Vol.96, No.3 PART 1 (1980), 490-493
Citation
P. Tanphaichitr, D. Tanphaichitr, J. Sureeratanan, S. Chatasingh (1980). Treatment of nephrotic syndrome with levamisole. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/11160.
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Treatment of nephrotic syndrome with levamisole
Alternative Title(s)
Author's Affiliation
Author's E-mail
Editor(s)
Editor's Affiliation
Corresponding Author(s)
Creator(s)
Compiler
Advisor(s)
Illustrator(s)
Applicant(s)
Inventor(s)
Issuer
Assignee
Other Contributor(s)
Series
Has Part
Abstract
Considerable evidence suggests a role of abnormal T-cell lymphocyte functions in the pathogenesis of minimal lesion nephrotic syndrome. The mean ± SD T-cell lymphocytes as determined by %E-rosettes among 10 children after 24 to 84 months of complete remission was 66.7±4.5; this is statistically different from that of seven children with minimal lesion nephrotic syndrome during relapse, 33.5±9.5 (P < 0.01). After levamisole therapy at 1.5 to 3.9 mg/kg/dose twice weekly for one to six months, the mean ±SD %E-rosettes in the latter group was 69.3±3.9, which is not statistically different from that in the group with complete remission after conventional treatment with steroids. Those treated with levamisole also had a complete remission without any side effects. © 1980 The C. V. Mosby Company.